Why Your CJC+Ipamorelin Isn't Working on Retatrutide

Your growth hormone peptides work through a specific chain of events, and if any link in that chain breaks, the whole thing falls apart.

Here is the full pathway: you inject a secretagogue like CJC-1295 or Ipamorelin, it travels to your pituitary gland, your pituitary releases a pulse of growth hormone into your blood, that growth hormone travels to your liver, and your liver converts it into something called IGF-1, which is insulin-like growth factor 1, the downstream signal that actually drives most of the benefits you are chasing. That is the chain. The article is about one specific place where Retatrutide breaks it.

The place it breaks is at the pituitary.

Your pituitary has receptors for insulin on the same cells that produce and release growth hormone, and when insulin is present in your blood, it binds to those receptors and suppresses growth hormone output. Think of insulin as the brake and your secretagogue injection as the gas pedal. You can press the gas as hard as you want, but if someone is riding the brake at the same time, you are not going anywhere. This is why the standard recommendation has always been to inject growth hormone secretagogues in a fasted state, because fasting is what keeps insulin low, which is what keeps the brake off.

The rule of thumb that emerged from this is to wait at least two hours after eating before you inject. And for most people not on any other compounds, two hours is a reasonable estimate of when insulin has returned close enough to baseline after a normal mixed meal.

Retatrutide changes this calculation entirely.

Retatrutide is a triple agonist, meaning it activates three receptors: GIP, GLP-1, and glucagon. Its GLP-1 activity is what matters here, because one of the things GLP-1 does is slow something called gastric emptying, which is simply the rate at which food leaves your stomach and moves into your small intestine where it gets absorbed. Slower gastric emptying means food sits in your stomach longer, which means it gets absorbed more slowly, which means insulin stays elevated for a longer window after you eat than it would in someone not on the drug.

Researchers have now measured exactly how much longer.

A 2023 study in Diabetes, Obesity and Metabolism measured gastric half-emptying time, which is the amount of time it takes for half of a meal to leave the stomach, on semaglutide versus placebo. Without the drug, the average half-emptying time was 118 minutes. On semaglutide, it rose to 171 minutes. That is roughly 45 minutes longer just to get halfway through the stomach. At the two-hour mark specifically, subjects on the GLP-1 drug had 25.5 percent more food still sitting in their stomach compared to placebo. At three hours, that gap had grown to 38 percent more retained, not less. The delay was not catching up over time. It was widening.

A separate analysis published in the Journal of Clinical Endocrinology and Metabolism found that patients on GLP-1 receptor agonists had gastric half-emptying times of 138 minutes compared to 95 minutes in controls. More importantly, that study found patients who had been fasting anywhere from 7 to 18 hours still had solid gastric contents present. This finding was significant enough that anesthesiologists began revising their pre-operative fasting protocols, because they could no longer assume the stomach was empty before putting a patient under general anesthesia even after a standard overnight fast.

Read that again in the context of your evening injection.

You eat dinner at 7pm. You wait the standard two hours. You inject at 9pm thinking you are in a fasted state. But on Retatrutide, food from that dinner is still being absorbed at 9pm, which means glucose is still entering your blood, which means insulin is still elevated, which means the brake is still on when you press the gas. You are paying for a growth hormone pulse you are not actually receiving.

This applies to every secretagogue that depends on fasted dosing: CJC-1295 with or without DAC, Ipamorelin, Tesamorelin, Sermorelin, GHRP-2, GHRP-6. The mechanism is the same across all of them.

The fix is straightforward. Move your injection to first thing in the morning, before eating anything.

After 8 to 10 hours of overnight sleep, even with Retatrutide slowing your digestion, your stomach has had enough time to clear and your insulin has had enough time to return to baseline. That overnight window is the one fasting period that Retatrutide's gastric slowing cannot meaningfully compress, because the delay it creates operates in hours, not across a full night.

One practical note on morning timing: research from a 1990 trial in the Journal of Clinical Endocrinology and Metabolism found that 24-hour IGF-1 levels were equivalent whether growth hormone was injected in the morning or the evening, which means you are not sacrificing any downstream benefit by shifting your window. What you are doing is making sure the injection actually works at all.

After you inject in the morning, wait 30 to 60 minutes before eating your first meal. That window allows the growth hormone pulse to complete before insulin rises again, and the subsequent meal then provides the insulin your liver needs to convert that growth hormone into IGF-1. You need insulin for that conversion step. Injecting into a permanently fasted state all day is not the goal. The goal is a clean, low-insulin window at the moment of the pulse, followed by normal eating afterward.

The broader point here is about what happens when you stack compounds with different mechanisms. Retatrutide is not interfering with CJC and Ipamorelin pharmacologically in any direct way. It is not binding to the same receptors or competing for the same enzymes. What it is doing is changing the physiological context in which the secretagogue is operating, and that context determines whether the injection works or does nothing. The drug interaction is not chemical. It is systemic. And that is the kind of interaction that never shows up on a standard drug interaction checker, which is exactly why understanding the underlying physiology matters more than following a rule someone else set for a different set of circumstances.

---

References

1. Urva S, Coskun T, Loghin C, et al. 2023. The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying. Diabetes, Obesity and Metabolism. Finding: Retatrutide at doses ≥3mg delayed acetaminophen Tmax by approximately 1 hour, with effects persisting at Day 30 and Day 79. Source
2. Jensterle M, et al. 2023. Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity. Diabetes, Obesity and Metabolism. Finding: Gastric half-emptying time increased from 118 minutes to 171 minutes on semaglutide. At 2 hours, 25.5% more gastric contents retained vs placebo. At 3 hours, 38% more retained. Source
3. Silveira SQ, et al. 2023. Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide. Journal of Clinical Endocrinology \& Metabolism. Finding: GLP-1 RA patients had gastric half-emptying of 138 minutes vs 95 minutes on placebo. Patients fasting 7-18 hours still had retained solid gastric contents. Source
4. Jorgensen JO, et al. 1990. Evening versus morning injections of growth hormone in GH-deficient patients: effects on 24-hour patterns of circulating hormones and metabolites. J Clin Endocrinol Metab. Finding: 24-hour IGF-1 levels were equivalent between morning and evening injection timing. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness